Trial Profile
A Phase 1b Study of Bcl-2 inhibition with ABT-199 in combination with tamoxifen in metastatic ER-positive breast cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Tamoxifen
- Indications Advanced breast cancer; Carcinoma; Male breast cancer
- Focus Adverse reactions
- Acronyms m-BEP
- 11 Dec 2020 Status changed from active, no longer recruiting to completed.
- 01 Dec 2020 Planned End Date changed from 6 Sep 2021 to 31 Dec 2022.
- 16 Aug 2018 Planned End Date changed from 1 Nov 2018 to 6 Sep 2021.